Khaberni - Researchers announced a striking scientific development that could change the future of kidney cancer treatment, after developing a new drug based on a smart mechanism that forces cancer cells to self-destruct instead of attacking them with traditional methods.
The American biotechnology company, "Neomorph," based in California, revealed the start of the first clinical trials of its new drug, NEO-811, designated for the treatment of clear cell renal cell carcinoma, the most common type of kidney cancer in the United States.
The drug relies on a technique known as "molecular glue," where it works to redirect natural enzymes inside the cell called E3 ubiquitin ligases to identify disease-causing proteins and classify them as waste, preparing them for dismantling and disposal, which ultimately leads to the cancer cell stopping growth or pushing it to self-destruct.
The first patient received the initial dose of the drug as part of the phase one/two clinical trials. The drug consists of small molecules that stimulate a forced reaction between cancer-causing proteins and the enzymes responsible for destroying them, which distinguishes it from traditional treatments that attack the cells directly. This type of medication is usually given orally and at regular doses.
The company explained that this mechanism could reduce long-term damage associated with chemotherapy or radiation treatment, such as nerve or organ damage or effects on fertility, given its reliance on stimulating natural mechanisms within the body rather than harsh intervention.
Dr. Phil Chamberlain, CEO and founder of "Neomorph," said that administering the first dose represents a milestone in the company's journey, confirming that clinical trials will provide vital data for the development of the drug and enhance the company's platform to offer innovative therapeutic solutions for patients whose medical needs are still unmet.
Clear cell renal carcinoma is known to start in the cells responsible for purifying blood from waste, and its occurrence is linked to several risk factors, including smoking, alcohol consumption, and exposure to certain environmental toxins. "Neomorph" focuses specifically on this type because of a common genetic mutation known as VHL, which plays a key role in stimulating tumor growth.
The company intends to later expand its research to include other types of cancer, while the date for announcing trial results or making the drug available to a broader group of patients has not yet been determined.
